Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy

Cisplatin combinations in cervical cancer—which is best?

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

We reviewed the results of the Gynecological Oncology Group 204 (GOG-204) randomized phase III trial, which investigated four cisplatin combination chemotherapy regimens for the treatment of patients with recurrent or metastatic cervical carcinoma. As the overall survival was similar between all arms, treatment recommendations need to be tailored based on toxic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jemal, A. et al. Cancer Statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  2. Thigpen, T., Shingleton, H., Homesley, H., Lagasse, L. & Blessing, J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48, 899–903 (1981).

    Article  CAS  Google Scholar 

  3. Monk, B. J. et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 27, 4649–4655 (2009).

    Article  CAS  Google Scholar 

  4. Robati, M., Holtz, D. & Dunton, C. J. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther. Clin. Risk Manag. 4, 213–218 (2008).

    Article  CAS  Google Scholar 

  5. Long, H. J. 3rd et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23, 4626–4633 (2005).

    Article  CAS  Google Scholar 

  6. Moore, D. H. et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J. Clin. Oncol. 22, 3113–3119 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology Lankenau Hospital, Lankenau Institute for Medical Research, Wynnewood, 19096, PA, USA

    David O. Holtz & Charles J. Dunton

Authors
  1. David O. Holtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles J. Dunton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles J. Dunton.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holtz, D., Dunton, C. Cisplatin combinations in cervical cancer—which is best?. Nat Rev Clin Oncol 7, 74–75 (2010). https://doi.org/10.1038/nrclinonc.2009.220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.220

  • Springer Nature Limited

Search

Navigation